Ivermectin in COVID-19 Management: What is the Current Evidence?

Madhavi      Eerike; Gerard   Marshall   Raj; Rekha      Priyadarshini; Gandham      Ravi; Debasis      Bisoi; Venu   Gopala Rao   Konda

doi:10.2174/1871526522666220119114035

Abstract

Ivermectin (IVM), an approved anthelminthic drug, has been reported to have antiviral, antibacterial, and anticancer activities. Antiviral activity is due to the inhibition of nuclear cargo importin (IMP) protein. The anti-SARS CoV-2 activity through in vitro study was first reported by an Australian team. Later, many studies were conducted, and most of the study results were available as non-peer-reviewed preprints. In this narrative review, literature on the clinical studies conducted with ivermectin from published articles, preprints, and unpublished evidence was collected until 13th June 2021. They are discussed based on the severity of COVID-19 disease. Out of the 23 peer-reviewed published articles, 13 studies were randomized controlled trials. The remaining were either prospective interventional, prospective observational, retrospective cohort, cross-sectional, or case series type of studies; additionally, there were 10 randomized controlled trials available as preprints. In most studies, ivermectin was used in combination with doxycycline, azithromycin, or other drugs. Some studies suggested that a higher dose or increased duration of ivermectin usage was required to achieve favorable effects. In this review, articles on the prophylactic role of ivermectin in COVID-19 are also discussed - wherein the results are more promising. Despite accumulating evidence suggesting the possible use of ivermectin, the final call to incorporate ivermectin in the management of COVID-19 is still inconclusive.

Keywords: Anthelminthic, antiviral, COVID-19, ivermectin, SARS CoV-2, importin protein.

[1] 
US-FDA Ivemectin(Stromectol) Label. 1998. Available from:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf
[2] 
Keiser J, McCarthy J, Hotez P. Chemotherapy of Helminth Infections.In: Brunton LL, Hilal-Dandan R, Knollmann BC, EdsGoodman & Gilman’s: The Pharmacological Basis of Therapeutics.  13th ed. New York: McGraw-Hill Education 2018; pp. 1001-9.
[3] 
Crump A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot (Tokyo)  2017; 70(5): 495-505.
[http://dx.doi.org/10.1038/ja.2017.11] [PMID: 28196978] 
[4] 
Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res  2020; 177: 104760.
[http://dx.doi.org/10.1016/j.antiviral.2020.104760] [PMID: 32135219] 
[5] 
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res  2020; 178: 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768] 
[6] 
US-FDA. FDA Letter to Stakeholders: Do Not Use Ivermectin Intended
for Animals as Treatment for COVID-19 in Humans.
2020. Available from:. https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans
[7] 
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res  2020; 178: 104805.
[http://dx.doi.org/10.1016/j.antiviral.2020.104805] [PMID: 32330482] 
[8] 
Schmith VD, Zhou JJ, Lohmer LRL. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther  2020; 108(4): 762-5.
[http://dx.doi.org/10.1002/cpt.1889] [PMID: 32378737] 
[9] 
Jermain B, Hanafin PO, Cao Y, Lifschitz A, Lanusse C, Rao GG. Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing. J Pharm Sci  2020; 109(12): 3574-8.
[http://dx.doi.org/10.1016/j.xphs.2020.08.024] [PMID: 32891630] 
[10] 
Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial.  E. Clinical Medicine  2021; 37: 100959.
[http://dx.doi.org/10.1016/j.eclinm.2021.100959] [PMID: 34189446] 
[11] 
WHO. WHO | Clinical management of COVID-19 - Interim guidance.
2019. Available from. https://www.who.int/publications/i/item/ clinical-management-of-covid-19.
[12] 
MOHFW, GoI. Clinical Management Protocol for COVID-19 (In
Adults). 2021. Available from. https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated 24052021.pdf
[13] 
Chowdhury ATMM, Shahbaz M, Karim MR, Islam J, Guo D, He S. A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients. EJMO  2021; 5(1): 63-70.
[http://dx.doi.org/10.14744/ejmo.2021.16263] 
[14] 
Gorial FI, Mashhadani S, Sayaly HM, et al.  Effectiveness of ivermectin
as add-on therapy in COVID-19 management (Pilot Trial).
medRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.07.20145979] 
[15] 
Carvallo HE, Hirsch RR, Farinella ME.  Safety and efficacy of the
combined use of ivermectin, dexamethasone, enoxaparin and aspirin
against COVID-19. medRxiv 2020.
[16] 
Morgenstern J, Redondo JN, De León A, et al. The use of compassionate ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of covid-19 at the medical center bournigal and the medical center puntacana, rescue group, dominican republic, from May 1 to August 10, 2020. J Clin Trials  2020; 11(S9): 1000002.
[17] 
Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Ahmed S. Controlled randomized clinical trial on using ivermectin with
doxycycline for treating COVID-19 patients in Baghdad, Iraq.
medRxiv 2020.. 
[http://dx.doi.org/10.1101/2020.10.26.20219345] 
[18] 
Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi- center clinical trial. ResearchSquare 2020.
[http://dx.doi.org/10.21203/rs.3.rs-109670/v1] 
[19] 
Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis  2021; 103: 214-6.
[http://dx.doi.org/10.1016/j.ijid.2020.11.191] [PMID: 33278625] 
[20] 
Elgazzar A, Hany B, Youssef SA, Hafez M, Moussa H, Eltaweel A. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square 2020.
[21] 
Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: A randomized trial. J Int Med Res  2021; 49(5): 3000605211013550.
[http://dx.doi.org/10.1177/03000605211013550] [PMID: 33983065] 
[22] 
Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in LagosQJM 2021; hcab035 
[http://dx.doi.org/10.1093/qjmed/hcab035] [PMID: 33599247] 
[23] 
Bukhari KHS, Asghar A, Perveen N, et al. Efficacy of ivermectin in COVID-19 patients with mild to moderate disease. MedRxiv 2021.
[http://dx.doi.org/10.1101/2021.02.02.21250840] 
[24] 
Samaha AA, Mouawia H, Fawaz M, et al. Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: A pilot clinical trial in Lebanon. Viruses  2021; 13(6): 989.
[http://dx.doi.org/10.3390/v13060989] [PMID: 34073401] 
[25] 
Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. Research Square 2021.
[http://dx.doi.org/10.21203/rs.3.rs-191648/v1] 
[26] 
Biber A, Mandelboim M, Harmelin G, et al.  Favorable outcome on
viral load and culture viability using Ivermectin in early treatment of
non-hospitalized patients with mild COVID-19 - A double-blind, randomized
placebo-controlled trial. medRxiv 2021.. 
[http://dx.doi.org/10.1101/2021.05.31.21258081] 
[27] 
Chahla RE, Ruiz LM, Mena T, et al. Cluster randomised trials - ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers. Research Square 2021.
[http://dx.doi.org/10.21203/rs.3.rs-495945/v1] 
[28] 
Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients. New Microbes New Infect  2021; 43: 100915.
[http://dx.doi.org/10.1016/j.nmni.2021.100915] [PMID: 34249367] 
[29] 
Spoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the treatment of SARS- CoV-2. Integr Arch Int Med  2020; 7(10): 177-82.
[30] 
Faisal R, Shah SFA, Hussain M. Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19. Prof Med J  2021; 28(5): 737-41.
[http://dx.doi.org/10.29309/TPMJ/2021.28.05.5867] 
[31] 
Pott-Junior H, Paoliello MMB, Miguel AQC, et al. Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicol Rep  2021; 8: 505-10.
[http://dx.doi.org/10.1016/j.toxrep.2021.03.003] [PMID: 33723507] 
[32] 
Alam MT, Murshed R, Bhiuyan E, Saber S, Alam R, Robin R. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. J Bangladesh Coll Phys Surg  2020; 38: 10-5.
[http://dx.doi.org/10.3329/jbcps.v38i0.47512] 
[33] 
Bhattacharya R, Gosh R, Kulshrestha M, Chowdury S, Mukherjee R, Ray I. Observational study on clinical features, treatment and outcome of COVID 19 in a tertiary care centre in India- a retrospective case series. Int J Sci Res   2020; 9: 69-71.
[http://dx.doi.org/10.36106/ijsr/7232245] 
[34] 
Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine  2021; 32: 100720.
[http://dx.doi.org/10.1016/j.eclinm.2020.100720] [PMID: 33495752] 
[35] 
Podder CH, Chowdhury N, Sina MI, Ul Haque WM. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC J Med Sci  2020; 14(2): 11-8.
[http://dx.doi.org/10.3329/imcjms.v14i2.52826] 
[36] 
Ravikirti Roy R, Pattadar C, Raj R, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: A double-blind randomized placebo controlled trial in Eastern India. J Pharm Pharm Sci  2021; 24: 343-50.
[http://dx.doi.org/10.18433/jpps32105] [PMID: 34265236] 
[37] 
López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial. JAMA  2021; 325(14): 1426-35.
[http://dx.doi.org/10.1001/jama.2021.3071] [PMID: 33662102] 
[38] 
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol  2021; 93(10): 5833-8.
[http://dx.doi.org/10.1002/jmv.27122] [PMID: 34076901] 
[39] 
Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in COVID nineteen study. Chest  2021; 159(1): 85-92.
[http://dx.doi.org/10.1016/j.chest.2020.10.009] [PMID: 33065103] 
[40] 
Okumuş N, Demirtürk N, Çetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis  2021; 21(1): 411.
[http://dx.doi.org/10.1186/s12879-021-06104-9] [PMID: 33947344] 
[41] 
Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of ivermectin in patients with COVID-19: A multicenter, double-blind, randomized, controlled clinical trial. Clin Ther  2021; 43(6): 1007-19.
[http://dx.doi.org/10.1016/j.clinthera.2021.04.007] [PMID: 34052007] 
[42] 
Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world effectiveness of hydroxychloroquine, azithromycin,
 and ivermectin among hospitalized COVID-19 patients: results of a
 target trial emulation using observational data from a nationwide
 healthcare system in Peru. medRxiv 2020.. 
[http://dx.doi.org/10.1101/2020.10.06.20208066] 
[43] 
Gonzalez JLB, Gámez MG, Enciso EAM, et al. Efficacy and safety of
ivermectin and hydroxychloroquine in patients with severe COVID-
19. A randomized controlled trial. medRxiv 2021.. 
[http://dx.doi.org/10.1101/2021.02.18.21252037] 
[44] 
NIH. Prophylactic ivermectin in COVID-19 contacts. 2020. Available
from: . https://clinicaltrials.gov/ct2/show/study/NCT04422561
[45] 
Chahla RE, Ruiz LM, Ortega ES, et al. A randomized trial - intensive
treatment based in ivermectin and iota-carrageenan as pre-exposure
prophylaxis for COVID- 19 in healthcare agents. medRxiv 2021. 
[http://dx.doi.org/10.1101/2021.03.26.21254398] 
[46] 
Héctor C, Roberto H, Psaltis A, Veronica C. Study of the efficacy and safety of topical ivermectin + iotacarrageenan in the prophylaxis against COVID-19 in health personnel. J Biomed Res Clin Invest  2020; 2(1): 1007.
[http://dx.doi.org/10.31546/2633-8653.1007] 
[47] 
Alam MT, Murshed R, Gomes PF, et al. Ivermectin as pre-exposure
prophylaxis for COVID-19 among healthcare providers in a selected
tertiary hospital in Dhaka - An observational study. Eur J Med Health
Sci 2020; 2: pp. (6)1-5.. 
[http://dx.doi.org/10.24018/ejmed.2020.2.6.599] 
[48] 
Morgenstern J, Redondo JN, Olavarría A, et al.  Retrospective cohort
study of ivermectin as a SARS-CoV-2 pre-exposure prophylaxis
method in Healthcare Workers. medRxiv 2021. . 
[http://dx.doi.org/10.1101/2021.04.10.21255248] 
[49] 
Behera P, Patro BK, Singh AK, et al. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One  2021; 16(2): e0247163.
[http://dx.doi.org/10.1371/journal.pone.0247163] [PMID: 33592050] 
[50] 
Seet RCS, Quek AML, Ooi DSQ, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. Int J Infect Dis  2021; 106: 314-22.
[http://dx.doi.org/10.1016/j.ijid.2021.04.035] [PMID: 33864917] 
[51] 
NIH. | U.S. NLM | ClinicalTrials.gov. Ivermectin | Completed Studies
| Studies without Results | Covid19. 2021. Available from:. https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=Covid19&recrs=e&age_v=&gndr=&type=&rslt=Without&Search=Apply
[52] 
 NIH | COVID-19 treatment guidelines-antiviral therapy-ivermectin
[Internet]. 2021. Available from: . https://www.covid19treatment-guidelines.nih.gov/antiviral-therapy/ivermectin/
[53] 
Australian guidelines for the clinical care of people with COVID-19.
2021. Available from:. https://app.magicapp.org/#/guideline/L4Q5An/section/LAzmVn.
[54] 
Mega ER. Latin America’s embrace of an unproven COVID treatment is hindering drug trials. Nature  2020; 586(7830): 481-2.
[http://dx.doi.org/10.1038/d41586-020-02958-2] [PMID: 33077974] 
[55] 
Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther  2021; 28(3): e299-318.
[http://dx.doi.org/10.1097/MJT.0000000000001377] [PMID: 34375047] 
[56] 
Bryant A, Lawrie TA, Doswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: A systematic review and meta-analysis. ResearchSquare 2021.
[http://dx.doi.org/10.31219/osf.io/k37ft] 
[57] 
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review
and meta-analysis of randomized controlled trials. medRxiv
2021.. 
[http://dx.doi.org/10.1101/2021.05.21.21257595] 
[58] 
Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamanchumo CJ, Silva-Rengifo C, Gonzales-Zamora J, Barboza JJ.  Outcomes of
ivermectin in the treatment of COVID-19: A systematic review and
meta-analysis. medRxiv 2021.. 
[http://dx.doi.org/10.1101/2021.01.26.21250420] 

Rights & Permissions Print Cite

Article Metrics

21

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871526522666220119114035	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

Ivermectin in COVID-19 Management: What is the Current Evidence?

Abstract Play Pause

Related Journals

Related Books

Abstract